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Abstract
Age is the major risk factor for many neurodegenerative diseases, including Alzheimer’s Disease (AD), for reasons that are
not clear. The association could indicate that the duration or degree of exposure to toxic proteins is important for
pathology, or that age itself increases susceptibility to protein toxicity. Using an inducible Drosophila model of AD, we
investigated these possibilities by varying the expression of an Ab42 transgene in neurons at different adult ages and
measuring the effects on Ab42 levels and associated pathological phenotypes. Acute induction of Arctic Ab42 in young
adult flies resulted in rapid expression and clearance of mRNA and soluble Arctic Ab42 protein, but in irreversible expression
of insoluble Arctic Ab42 peptide. Arctic Ab42 peptide levels accumulated with longer durations of induction, and this led to
a dose-dependent reduction in negative geotaxis and lifespan. For a standardised level of mRNA expression, older flies had
higher levels of Arctic Ab42 peptide and associated toxicity, and this correlated with an age-dependent reduction in
proteasome activity. Equalising Ab42 protein at different ages shortened lifespan in correlation with the duration of
exposure to the peptide, suggesting that Ab42 expression accumulates damage over time. However, the relative reduction
in lifespan compared to controls was greater in flies first exposed to the peptide at older ages, suggesting that ageing itself
also increases susceptibility to Ab42 toxicity. Indeed older flies were more vulnerable to chronic Ab42 toxicity even with a
much lower lifetime exposure to the peptide. Finally, the persistence of insoluble Ab42 in both young and old induced flies
suggests that aggregated forms of the peptide cause toxicity in later life. Our results suggest that reduced protein turnover,
increased duration of exposure and increased vulnerability to protein toxicity at later ages in combination could explain the
late age-of-onset of neurodegenerative phenotypes.
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Introduction
Ageing is the major risk factor for common, chronic, killer
conditions, including cancer, cardiovascular disease and neurode-
generation. The aetiology of many neurodegenerative diseases
includes the formation of toxic protein aggregates in neurons. For
instance Alzheimer’s disease (AD), the most prevalent form of
senile dementia, is characterised by the widespread presence of
extracellular amyloid plaques, predominantly composed of amy-
loid beta (Ab) peptides, and intraneuronal neurofibrillary tangles
formed from insoluble fibrillar aggregates of the microtubule-
binding protein tau [1]. Most cases of AD (.99%) are sporadic
[2], with age as the main risk factor [3,4].
A large body of evidence suggests that the accumulation and
deposition of Ab peptides are the primary influence driving the
disease [5,6]. Support for this ‘amyloid cascade’ hypothesis comes
from mutations causing early-onset, familial AD (FAD), which
affect the amyloid precursor protein (APP), from which Ab
peptides are derived, and presenilins PS1 and PS2, which are
involved in the cleavage of APP to yield Ab peptides. These
mutations increase production of Ab, levels of Ab42 relative to
Ab40 or the propensity of Ab42 to aggregate (for review see [7]).
In addition, many mouse models of AD, typically based on the
overexpression of FAD associated APP alone or in combination
with mutations in PS1, develop age-dependent Ab plaques and
behavioral and memory deficits [8]. Furthermore, studies in the
fruit fly Drosophila melanogaster [9,10,11,12] and the nematode worm
Caenorhabditis elegans [13,14] have demonstrated that direct
expression of the toxic Ab42 peptide leads to an age-dependent
accumulation of Ab42, neuronal dysfunction and shortened
lifespan.
Other neurodegenerative conditions share both the aggregation
of toxic protein and a late age of onset [15]. For instance,
Parkinson’s Disease is associated with aggregation of a-synuclein
in Lewy bodies, with most cases sporadic and age the main risk
factor [16]. However the mechanisms linking protein aggregation
and the appearance of disease to age remain to be identified.
Protein aggregation may accumulate to a toxic threshold, or the
duration and extent of exposure may be important for inducing
neuronal dysfunction. In addition, the ageing process itself could
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increase vulnerability to toxic proteins by impairing their
clearance or increasing vulnerability to their toxic effects
[15,17]. All of these factors could be important – they are not
mutually exclusive.
To investigate the mechanisms linking protein toxicity to age,
we have induced expression of a toxic protein at different ages in
neurons of adult Drosophila. If ageing plays a direct role then we
would expect that standardised exposure of older neurons to a
transgene encoding a toxic protein would lead either to greater
levels of toxic protein, or greater toxicity of a standard dose of
protein, in older flies. The few studies that have addressed this
issue have suggested that ageing is indeed important. Brewer et al.,
(1998) isolated neurons from embryonic, young and old-aged rat
hippocampus and exposed them to toxic Ab fragments (25–35)
finding that toxicity, as measured by cell death, was age-, dose-
and time-dependent. Guela et al., (1998) demonstrated that aged
rhesus monkeys were more vulnerable than young to injected
plaque-equivalent concentrations of fibrillar Ab, with the young
monkeys developing no pathology at all. However, these studies
used either extracellular application of Ab fragments or microin-
jection of fibrillar Ab to induce toxicity, which makes some
assumptions about the nature and site of Ab toxicity. Evidence is
increasing that intracellular [18], soluble oligomers of Ab, rather
than extracellular, fibrillar forms of the peptide, are pathogenic
[19]. Furthermore, ageing could increase vulnerability to Ab
toxicity through the mechanisms by which the peptide is produced
and broken down. Hence, we have taken advantage of powerful
systems for conditional and tissue-specific gene over-expression in
Drosophila [20] to examine the effects of age on Ab peptide toxicity
under physiological conditions in vivo.
We have previously shown that induced expression of the FAD-
associated Arctic Ab42 (Arc Ab42) isoform in adult neurons of
Drosophila results in age-dependent locomotor and electrophysio-
logical deficits and shortened lifespan [21]. In the present study,
we show that these pathological phenotypes are dependent on the
concentration of Ab42. For equivalent Ab42 mRNA levels, higher
levels of Arc Ab42 peptide were present in older flies, and this
correlated with an age-dependent reduction in proteasome activity
and resulted in shortened lifespan. Controlling for this age-
dependent reduction in protein turnover, expression of equivalent
amounts of Ab42 protein at different ages shortened lifespan in
correlation with the duration of exposure to the peptide. This
suggests that the relationship between Ab42 toxicity and age
reflects an accumulation of damage over time. Despite this,
however, the relative reduction in lifespan compared to non-Arctic
Ab42-expressing controls was greater in flies first exposed to the
peptide at older ages, suggesting that ageing itself also increases
susceptibility to Ab42 toxicity. Indeed older flies were more
vulnerable to death from even much lower levels of exposure to
Ab42 protein. Our results therefore suggest that increasing age is
associated with greater protein toxicity through a combination of
reduced clearance, increased exposure and increased vulnerability
to pathogenic proteins.
Results
Dynamics of Ab42 expression and toxicity using the
elavGS-UAS system
We previously characterised an adult-onset, fly model of
Alzheimer’s disease [21], generated by expressing the Arctic
Ab42 peptide (UAS-Arc Ab42; [11]) under the control of an
RU486-inducible pan-neuronal driver (elav GeneSwitch (elavGS);
[20,22]). Under chronic induction conditions the levels of Arc
Ab42 mRNA and protein expression appeared to vary with age
[21]. Ab42 RNA expression declined with age, probably reflecting
a lower intake of the RU486 inducer as a consequence of the
known age-dependent reduction in feeding behaviour [23],
whereas protein levels increased with age, reflecting either a
time-dependent accumulation of the peptide or an age-dependent
reduction in protein turnover, or both. We now show further that,
under acute induction conditions, Ab42 mRNA (Figure 1A) and
soluble protein (Figure 1B) levels are rapidly cleared following
removal of RU486, whereas aggregated forms of the peptide are
stable for up to one week (Figure 1B). Varying the duration of
RU486 exposure for 2, 4, 7 or 14 days (see Table S1 for pulse
conditions), did not alter the level of Arc Ab42 mRNA expressed
at the end of the induction period (Figure 1C), suggesting that the
age-dependent reduction in transcript observed under chronic
conditions occurs at ages over 21 days. The concentration of Arc
Ab42 protein increased in correlation with the duration of RU486
exposure (Figure 1D) and this led to progressively more severe
reductions in negative geotaxis (Figure 1E) and survival (Figure 1F),
presumably due to the persistence of insoluble forms of peptide
after cessation of induction of gene expression.
Age-dependent reduction in protein turnover correlates
with Ab42 peptide accumulation and toxicity
We next aimed to use our inducible model to investigate the
intrinsic effects of age on vulnerability to Ab42 toxicity, by
inducing comparable levels of Arc Ab42 at different ages and
measuring the time to develop, and extent of, the subsequent
reduction in survival. This output variable allowed us to induce
Ab42 expression at a wide range of ages prior to the onset of
ageing-related deaths, unlike negative geotaxis, which starts to
decline already in the first week of life. Notably, chronic
administration of RU486 at the highest (200 mM) dose used in
our study had no effect on lifespan of non-Ab42-expressing flies
(Figure S1), demonstrating that our observed effects of Ab42
induction on survival are not attributable to the RU486 treatment
conditions.
Our analysis of the dynamics of Ab42 expression, as described
above, suggested that to standardise Ab42 levels at different ages
both the concentration of RU486 and the length of exposure to
the inducer must be finely tuned. We first equalised expression
levels of Ab42 mRNA in flies at day 5 or day 20 post-eclosion, by
varying the concentration of RU486, inducing for 1 week and
measuring transcript levels at the end of the induction period
(Figure S2). Induction at all RU486 concentrations produced
significant (P,0.05) Ab42 over-expression, and levels of Ab42
mRNA were similar in flies induced at day 5 with 50 mM (RU 50
[5–12d]) and at day 20 with 200 mM (RU 200 [20–27d]) RU486,
respectively (Figures 2A and S2). However, these standardised
levels of mRNA expression led to different levels of Ab42 protein,
measured at the end of the 1-week pulse (0d) and 1, 2 and 3 weeks
following switch-off (Figure 2B). Total Arctic Ab42 peptide levels
were significantly higher (P,0.0001, two-way ANOVA) in RU
200 [20–27d] than in RU 50 [5–12d] induced flies, and no
significant reduction occurred for up to 3 weeks following switch-
off in either age group, further confirming that Arctic Ab42
peptide is highly resistant to degradation. Presumably associated
with the higher levels of Arctic Ab42 peptide present in the day-
20-induced flies (RU 200 [20–27d]), only they displayed a
shortened lifespan in response to Ab42 expression (Figure 2C).
For a given level of mRNA, older flies thus had higher levels of
Ab42 peptide. Protein turnover declines with age in several
organisms [24,25], suggesting that age-dependent effects on
protein synthesis or degradation could explain the accumulation
of Ab42 peptide in older flies. As a measure of the rate of
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Figure 1. Effects of varying RU486 exposure time on Ab42 levels and toxicity. 2-day-old UAS-Arc Ab42/+; elavGS/+ females were treated
with 200 mM RU486 for 2, 4, 7 or 14 days before being transferred to RU486-free medium (see table S1 for pulse conditions). Flies maintained
chronically on – RU486 (2RU) and 200 mM RU486 (+RU) were used as negative and positive controls, respectively. Data are presented as means 6
SEM and were analysed by ANOVA followed by Tukey’s honestly significant difference (HSD) post-hoc test. (A & B) Removal of RU486 resulted in rapid
clearance of Arctic Ab42 mRNA as well as soluble, but not insoluble, protein levels. (A) Ab42 mRNA levels were measured by quantitative RT PCR prior
to RU486 treatment (2RU), at the end of treatment (+RU 7 d), and at the indicated time-points following the switch to RU486-free food (see
methods). ***P,0.001 comparing the level of Arctic Ab42 mRNA at the end of RU treatment to all other conditions (n = 3). (B) Soluble and insoluble
Arctic Ab42 was fractionated (see methods) and measured by ELISA at the indicated time-points (n = 3). P,0.0001 comparing soluble and insoluble
Ab42 fractions (two-way ANOVA). Soluble Ab42 was reduced to baseline levels following switch-off (see inset; *P,0.05 comparing +RU 7d to 2 or 7d
following transfer to 2RU food and no significant difference comparing 2 or 7d following switch to 2RU to non-RU-treated controls; Tukey’s HSD),
whereas insoluble Ab42 was highly stable for 1 week following cessation of transgene expression (no significant difference between +RU 7d and 2 or
7d following switch to 2RU, Tukey’s HSD). (C–F) Arctic Ab42 protein levels correlate with increasing duration of RU486 exposure and associate with
impairments in function. (C) Arctic Ab42 mRNA levels were quantified at the end of each RU486 pulse, as indicated. Ab42 transcript was significantly
increased under all RU treatment conditions compared to untreated controls (***P,0.001, n = 5, Tukey’s HSD), with no significant difference (n.s.)
between the varying RU486 pulse conditions. (D) Total (soluble and insoluble) Ab42 peptide was extracted using Guanidine HCl and levels were
measured by ELISA at the end of each RU486 pulse (see methods). Total Arctic Ab42 protein levels increased with the length of RU486 exposure
(P,0.0001, one-way ANOVA, n = 3). *P,0.05 comparing 2, 4 and 7 day pulses, but no significant difference between 7 and 14 day pulses. P,0.05
comparing 2RU to all + RU treatments conditions (Tukey’s HSD). (E) Climbing ability was assessed at the indicated time-points. Arrows indicate the
period of RU486 treatment for each pulse. Data were analysed by two-way ANOVA and Tukey’s HSD (n = 3, number of flies per group= 39–45).
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translation, 35S-methionine incorporation was assessed in day-2
(RU 50 [2–9d]) and day-20 (RU 200 [20–27d]) UAS-Arc Ab42;
elavGS flies pulsed with RU486 for 1 week. 35S-methionine
incorporation was significantly lower in RU 200 [20–27d] flies,
indicating a reduced rate of translation (Figure 2D). An increase in
protein synthesis is, therefore, unlikely to explain the accumulation
of Arc Ab42 peptide in older flies. However, proteasome activity
was also significantly reduced in RU 200 [20–27d] compared to
RU 50 [2–9d] Arc Ab42 over-expressing flies, as well as in older
non-RU-treated flies (Figure 2E) and elavGS driver flies alone
under the same treatment conditions (Figure S3), suggesting a
general age-dependent reduction in proteasomal degradation
which may account for the higher levels of the Ab42 peptide
following induction in older flies and, at least in part, for the
consequently increased toxicity.
Duration of exposure and ageing per se increase
vulnerability to insoluble Arctic Ab42 peptide
To measure the vulnerability of older flies to protein toxicity per
se, we next aimed to control for changes in the rate of protein
turnover with age by producing standardised levels of Ab42
peptide at different ages. UAS-Arc Ab42; elavGS flies were treated
with a range of RU486 doses (50–200 mM RU) for varying
exposure times (1 or 2 weeks) from 5, 20 and 30 days of age. At
the end of the induction period, total Ab42 peptide concentration
was measured (Figure S4). A variety of treatments resulted in
equivalent levels of Ab42 peptide at different ages (Figure S4; non-
significant difference in Ab42 peptide levels); (1) a 2 week pulse of
100 mM RU in 5-day old flies (RU 100 [5–19d]) versus 200 mM
RU in 20-day (RU 200 [20–34d]) and 30-day (RU 200 [30–44d])
old flies and (2) a 1 week pulse of 200 mM RU in 5-day (RU 200
[5–12d]) versus 20-day (RU 200 [20–27d]) old flies.
Arctic Ab42 toxicity was assessed by measuring survival under
the RU486 treatment conditions described in (1) above (Figures 3
and S5A). Equivalent levels of Ab42 peptide expression were again
confirmed at the end of the 2 week induction period in day-5, day-
20 and day-30-induced flies (Figur 3A). All RU-treated flies had
reduced median lifespan compared to non-RU-treated controls:
27% for RU 100 [5–19d], 24% for RU 200 [20–34d] and 14% for
RU 200 [30–44d] (Figure S5A). Measuring survival from 44 days
only, when Ab42 peptide (which once present is not cleared) and
age are equivalent in all treatment groups, young-induced flies had
a shorter life expectancy compared to old-induced flies (Figur-
e S5B). This suggests that susceptibility to Ab42 toxicity correlates
with the duration of exposure to the peptide, most probably
reflecting an accumulation of damage over time. To isolate the
effect of age specifically on vulnerability to Arc Ab42 toxicity,
further data analysis controlled for both the duration of exposure
to insoluble Arc Ab42 protein and the direct effect of age on
survival (Figure 3B), with older flies expected to die sooner even in
the absence of any Arc Ab42. To control for the longer exposure
to Ab42 in younger flies, we re-analysed survival as function of
time from the age of induction. To control for the direct effect
of age on survival, we expressed survival as a percentage of that
of non-RU-treated controls at each time-point from the age of
induction. Relative survival following RU486 treatment was
progressively lower in the two groups of older flies (Figure 3B;
P,0.05 comparing RU 100 [5–19d] flies to RU 200 [20–34d] and
RU 200 [30–44d] flies; P,0.05 comparing RU 200 [20–34d] and
RU 200 [30–44d] flies, Wilcoxon rank sign test), suggesting that
ageing itself also increases vulnerability to toxicity from a standard
dose of Ab42 peptide. Finally, measuring relative survival of RU
100 [5–19d] flies from progressively later time-points (Figure S5C)
revealed that flies over-expressing Arctic Ab42 early in life were
more severely disadvantaged in their survival compared to controls
at older ages. This reduced survival with age may be attributable
to an accumulation of damage with time, as indicated by the
increase in toxicity with longer exposures to Ab42 peptide
(Figure S5B), or an ageing-dependent increase in susceptibility to
Ab42 toxicity (Figure 3B), or both.
We next examined whether the increased vulnerability of older
flies to Ab42 toxicity was due to differences in protein aggregation
with age. To standardise the dose of total Ab42 peptide at different
ages, UAS-Arc Ab42; elavGS flies were induced for 1 week as
described in (2) above. Soluble and insoluble proteins were then
separated and Ab42 measured in each fraction at 1 and 7 days
after induction, then at 7, 21 and, in the case of RU 200 [5–12d]-
induced flies, 35 days following switch-off (Figure 3C). Equivalent
levels of Ab42 were detected in soluble and insoluble pools
immediately following RU treatment (no significant difference
comparing insoluble Ab42 at 1 day versus soluble Ab42 at 1 and
7 days following RU486 treatment). Ab42 aggregated during the
induction period with a significant increase in insoluble Ab42
between 1 and 7 days following RU treatment (P=0.016
comparing flies on RU for 1 day versus 7 days). Soluble Ab42
was cleared to baseline levels within 1 week following switch-off,
but insoluble protein remained stable with no significant reduction
in peptide levels for several weeks following transfer to RU486-free
food (P=0.886 comparing flies switched to –RU486 food to those
at the end of the 7 day induction period). No significant difference
in the rate of Ab42 aggregation or clearance was observed
between young and old-induced flies (P=0.428 comparing
soluble, and P=0.258 comparing insoluble, Ab42 levels between
RU 200 [5–12d] and RU 200 [20–27d]-induced flies). Hence,
older flies were more susceptible to the same form of Ab42 as is
present in young flies. Moreover, the majority of Arc Ab42 was
insoluble at late time-points in both RU 200 [5–12d] and RU 200
[20–27d]-induced flies, suggesting that insoluble forms of the
peptide are involved in inducing toxicity later in life.
Older flies are more vulnerable to chronic Ab42, despite a
lower lifetime exposure to the peptide
Finally, we examined the effects of age on Ab42 toxicity when
induced chronically, to allow protein to accumulate continuously
under conditions that may more closely re-capitulate the disease
situation. UAS-Arctic Ab42; elavGS flies were induced from
2 days and 20 days post-eclosion and total Arctic Ab42 protein
levels assayed every 5 days until death (Figure 4A & B). Arctic
Ab42 accumulated following induction in both RU 200 [2d
chronic] and RU 200 [20d chronic]-induced flies, but at a slower
rate and to a much lower maximum concentration in older flies
(Figure 4A). This most probably reflects reduced induction of gene
Negative geotaxis decreased with increasing RU486 exposure length. Pulse lengths $4 days were significantly different from 2RU controls, whereas
pulse lengths #4 days were significantly different from chronically treated (+RU) controls (P,0.05, Tukey’s HSD). A 2-day pulse of RU486 did not
significantly induce climbing defects compared to untreated flies, whereas a 7-day pulse did not significantly improve the reduced climbing ability
compared to chronically treated +RU controls. (F) Survival decreased with increasing RU486 exposure time. Median lifespans were: 62 days for –RU
(chronic), 55 days for +2d RU, 52 days for +4d RU, 45 days for +7d RU and 27 days for + RU (chronic). All survival curves were significantly different
from each other (P,0.001, log rank test).
doi:10.1371/journal.pone.0040569.g001
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200 mM RU (RU 200 [20–27d]). Ab42 mRNA, lifespan and protein levels were then measured. Data are presented as means 6 SEM. (A) Arctic Ab42
transcripts were measured at the end of the induction period (see methods). Ab42 transcript levels were not significantly different between RU 50 [5–
12d] and RU 200 [20–27d] flies under these induction conditions (P=0.5, student’s t-test, n = 4). A more detailed analysis of Ab42 expression levels at
varying RU486 concentrations can be found in Fig S1. (B) Arctic Ab42 peptide accumulates in older flies at equivalent levels of Ab42 mRNA. Total
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significant difference in protein levels was observed up to 3 weeks following switch-off at either age of induction (P= 0.382). (C) Equivalent levels of
Ab42 transcripts reduced survival only when induced in old flies (RU 200 [20–27d]). Arrows indicate the period of RU486 treatment. Median lifespans
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(n = 5). *** P,0.0001 comparing 9 versus 27 day-old flies, P= 0.429 comparing + versus – RU486 (two-way ANOVA); P,0.05 comparing RU 50 [2–9d]
to RU 200 [20–27d] flies and –RU day 9 to –RU day 27 flies (Tukey’s HSD).
doi:10.1371/journal.pone.0040569.g002
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post-eclosion, and were maintained on RU486-free medium prior to and following the pulse period. (A) Total Ab42 protein levels (soluble and
insoluble as measured by GnHCl extraction) were equivalent at the end of the RU pulse when comparing each age of induction. Data are expressed as
means 6 SEM (n = 5) and were compared using one-way ANOVA and Tukey’s HSD post-hoc. No significant differences were observed. (B) Survival,
expressed as a percentage of non-RU486-treated controls, plotted from the age of RU486 induction. Arrow indicates the induction period. Older flies
exhibit a significantly greater reduction in relative survival following RU treatment (P,0.05 comparing RU 200 [20–34d] and RU 200 [30–44d] with RU
100 [5–19d] and RU 200 [20–34d] with RU 200 [30–44d], Wilcoxon matched pairs sign rank test). Raw survival curves are depicted in Fig S4A. (C) UAS-
Arctic Ab42/+; elavGS/+ females were pulsed for 1 week with 200 mM RU486 from 5 (RU 200 [5–12d]) and 20 (RU 200 [20–27d]) days post-eclosion, to
equalise the total Ab42 level in young versus old-induced flies (see Fig S3). Soluble and insoluble Ab42 was fractionated (see methods) and measured
by ELISA at 1 and 7 days following induction, then 7, 21 and, in the case of RU 200 [5–12d] flies, 35 days following the switch to RU486-free food.
Data are expressed as means 6 SEM and were analysed by two-way ANOVA (n= 4). No significant differences were observed comparing RU 200 [5–
12d] versus RU 200 [20–27d]-induced flies for either soluble (P=0.428) or insoluble (P= 0.258) Ab42 fractions. Equivalent levels of soluble and
insoluble Ab42 were observed 1 day following induction (n.s. difference between insoluble Ab42 at day 1 versus soluble Ab42 at days 1 and 7
following RU treatment). Soluble Ab42 levels did not vary significantly during the induction period (P= 0.546 comparing flies on RU486 for 1 day
versus 7 days). Soluble Ab42 was significantly reduced following switch-off (P,0.001 comparing flies at the end of the 7-day induction period with
flies switched to 2RU food), reaching baseline levels within 7 days (P= 0.99 comparing RU 200 [5–12d] flies switched to 2RU food for 7, 21 and
35 days and P= 0.628 comparing RU 200 [20–27d] flies switched to 2RU for 7 and 21 days). Insoluble Ab42 levels increased significantly during the
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expression caused by age-dependent reductions in feeding
behaviour, and therefore consumption of inducer, in older flies.
The area under the curve of Ab42 accumulation across time was
calculated as a crude measure of lifetime exposure to Ab42 in RU
200 [2d chronic] and RU 200 [20d chronic]- induced flies,
revealing that old-induced flies were exposed to 7.3 fold lower
Ab42 from induction until death than young-induced flies
(Figure 4B).
Survival was significantly more reduced in RU 200 [2d chronic]
than in RU 200 [20d chronic]-treated flies (Figure S5B, 45%
versus 25%, P,0.05, log rank test), possibly due to either the
longer duration of exposure or increased concentration of the
peptide in young-induced flies. However, as described above, we
controlled for the longer exposure to Ab42 in young-induced flies,
by re-calculating survival as function of the time from the age of
induction, and for the effects of age on survival by expressing
survival as a percentage of non-RU-treated controls at each time-
point (Figure 4C). Remarkably, RU 200 [20d chronic]-induced
flies exhibited a significantly greater reduction in relative survival
than did RU 200 [2d chronic]-induced flies (P,0.05, Wilcoxon
matched pairs sign rank test). Since old-induced flies were exposed
to much lower maximum and cumulative amounts of Ab42
peptide, these results further support the conclusion that older flies
are more vulnerable to Arctic Ab42 protein toxicity.
RU486 induction period (P= 0.016 comparing flies on RU486 for 1 day versus 7 days, P,0.05 comparing insoluble Ab42 levels in flies on RU for 7 days
versus soluble Ab42 levels at days 1 and 7 following induction). Insoluble Ab42 was not significantly reduced following switch-off (P=0.886
comparing flies at the end of the 7-day induction period with flies switched to2RU food) and remained stable for several weeks following transfer to
RU486-free food (P=0.744 comparing RU 200 [5–12d] flies switched to2RU food for 7, 21 and 35 days and P=0.748 comparing RU 200 [20–27d] flies
switched to 2RU for 7 and 21 days).
doi:10.1371/journal.pone.0040569.g003
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Figure 4. Older flies are more vulnerable to chronically induced Arctic Ab42, despite a lower lifetime exposure to the peptide. (A)
UAS-Arctic Ab42/+; elavGS/+ females were chronically treated with 200 mM RU486 from 2-days (RU 200 [2d chronic]) and 20-days (RU 200 [20d
chronic]) post eclosion. Total (soluble and insoluble) Arctic Ab42 protein levels were assayed every 5 days until flies started dying. Data are presented
as means 6 SEM and were analysed by two-way ANOVA and Tukey’s HSD (n = 3). Ab42 levels were higher in RU 200 [2d chronic] versus RU 200 [20d
chronic] flies at all time-points up to 25 days post-induction (P,0.05, Tukey’s HSD) except day 5. (B) A crude measure of the lifetime Arctic Ab42 load
(from induction until the start of decline in survival) was determined in 2d and 20d-induced flies by calculating the area under the curves in (A). Data
are presented as the means 6 SEM (n= 3). The lifetime Arctic Ab42 load was significantly lower in RU 200 [20d chronic] than in RU 200 [2d chronic]-
treated flies (**P,0.01, student’s t-test). (C) Survival, expressed as a percentage of non-RU486-treated controls, plotted from the age of RU486
induction. RU 200 [20d chronic] flies exhibited a significant reduction in relative survival following RU486 treatment compared to RU 200 [2d chronic]
flies (P,0.05, Wilcoxon matched pairs sign rank test). Original survival curves are depicted in Fig S4B.
doi:10.1371/journal.pone.0040569.g004
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Discussion
Many neurodegenerative diseases share in common the
accumulation of toxic proteins and a late age of onset [15]. Our
study aimed to address the mechanisms linking protein toxicity to
age, by inducing expression of a transgene encoding the toxic
Arctic Ab42 peptide at different ages and measuring the effects on
levels of the toxic peptide and the extent of the resulting pathology.
Although the inducible GeneSwitch (GS) system has been
widely used to study both ageing [26] and neurodegeneration [22],
most studies have examined the effects of chronic induction.
Characterisation of the dynamics of Ab42 expression using our
GS-inducible AD model [21] was, therefore, required. The
responses of Ab42 mRNA and peptide to cessation of induction
differed, with a rapid return to baseline levels of mRNA and
soluble Ab42 expression, but insoluble Ab42 peptide levels
remained stable for several weeks. Importantly, switching-off
transgene expression in young flies did not reverse Ab42 toxicity,
because both subsequent climbing ability and survival were
reduced in a dose-dependent manner, probably attributable to
the persistence of the highly stable, insoluble Ab42 peptide.
Studies using inducible APP mouse models of AD are congruent
with these observations, because APP expression and Ab
production are suppressed upon removal of the inducer doxycy-
line, but the mice retain a considerable Ab load for the following
six months [27,28]. The high stability of insoluble Ab42 in our fly
model may be related to the ability of the Arctic mutation to
promote rapid aggregation [29]. The ZAb3 Affibody, a conforma-
tion-specific Ab binding protein that prevents Ab42 aggregation,
clears Ab42 and rescues toxicity when co-expressed with Arctic
Ab42 in Drosophila neurons [30], suggesting that aggregated Ab42
can indeed induce neuropathological phenotypes in the fly.
We found that Ab42 toxicity is related to the concentration of
the peptide, with a dose-response in negative geotaxis and lifespan,
in agreement with previous studies in cells showing that toxicity is
dependent upon the dose of Ab42 [31]. Importantly, when Ab42
mRNA levels were equalised at different ages of induction, Ab42
peptide accumulated to higher levels in older-induced flies, and
subsequently shortened lifespan only when induced at later time-
points. This difference correlated with an alteration in protein
turnover with age [24]. Measurement of 35S-Methionine incor-
poration showed that general protein translation was reduced in
older flies, consistent with published studies showing that the rate
of protein synthesis decreases with age in a wide variety of cells,
tissues, organs and organisms, including humans (reviewed in
[25]). As there is no pronounced reduction in protein mass with
age [32], this reduction in protein synthesis must be accompanied
by a reduction in protein degradation, and indeed we found that
proteasome activity declined with age. Reduced autophagy and
activity of Ab42-degrading enzymes such as insulin degrading
enzyme [33,34] and neprilysin [35] could also potentially
contribute to a reduced rate of degradation of Ab42 peptide at
later ages.
We then examined the intrinsic effect of age on vulnerability to
protein toxicity by inducing a fixed level of Ab42 peptide in flies of
different ages. Due to the persistence of Arctic Ab42 peptide, at
the end of the oldest induction period all treatment groups
expressed the same level of Ab42 at the same age. Measuring
lifespan from this time-point only (44 days of age) revealed that
those flies exposed to Ab42 peptide for longer had a reduced
survival, suggesting that the connection between age and Ab42
toxicity, in part, reflects an accumulation of damage over time.
However, in order to isolate the effect of age specifically on Ab42
toxicity we controlled for the different durations of exposure by
measuring survival from the time of transgene induction, and for
the direct effect of ageing on lifespan by measuring the
proportional reduction in survival compared to un-induced flies
of the same age. This may explain why our conclusions differ from
those of an earlier study, using a similar experimental design [36].
At standardised levels of mRNA expression, Ling et al., observed a
shorter maximum lifespan in young-induced flies compared to old-
induced flies, as did we, but concluded that younger flies were
therefore more vulnerable to Ab42 toxicity. However, the effects
of age on protein turnover and survival were not considered, and
our study highlights the importance of controlling for effects of age
on protein turnover, duration of exposure and the direct effect of
ageing on the output variable when investigating the relationship
between ageing and protein toxicity. Our analysis showed that the
relative survival of older flies was more reduced than that of young
flies by an equivalent dose of Ab42 peptide, indicating that ageing
itself increased their vulnerability. Moreover this age-dependent
increase in susceptibility appeared to be independent of the rate of
Arc Ab42 aggregation, suggesting that the relationship between
age and the onset of proteotoxicity is not only due to the time
required for an otherwise asymptomatic protein to become
pathogenic.
Chronic over-expression of Arctic Ab42 was also more toxic to
older flies, despite a significantly lower duration of exposure,
maximum concentration and lifetime Arctic Ab42 burden. Thus,
in all instances, either the equivalent or a lower Arctic Ab42 load
resulted in relatively higher levels of toxicity per time of exposure
in older flies, demonstrating that ageing does increase vulnerability
to protein-mediated toxicity. These results agree with other studies
demonstrating that older neurons are more vulnerable to
extracellularly applied Ab42 fibrils both in cell culture [31] and
in the brain of rhesus monkeys [37]. Our study builds upon these
findings by providing the first evidence that this is the case in vivo
under physiological conditions of Ab42 expression and aggrega-
tion.
Our study suggests that, in addition to an accumulation of
damage over time, ageing results in lowered degradation of a toxic
protein and in increased vulnerability to its toxic effects. Hence,
both the duration of exposure to toxic protein and the ageing
process itself may contribute to making age the main risk factor for
protein toxicity and neurodegeneration.
Materials and Methods
Fly stocks and husbandry
All fly stocks were maintained at 25uC on a 12:12-h light:dark
cycle at constant humidity on a standard sugar-yeast (SY) medium
(15 gl21 agar, 50 gl21 sugar, 100 gl21 autolysed yeast, 100 gl21
nipagin and 3 ml l21 propionic acid). Adult-onset neuronal-
specific expression of Arctic mutant Ab42 peptide was achieved by
using the elav GeneSwitch (elavGS)-UAS system [GAL4-depen-
dant upstream activator sequence; ElavGS was derived from the
original elavGS 301.2 line and obtained as a generous gift from Dr
H. Tricoire (CNRS, France). UAS-ArcAb42 was obtained from
Dr D. Crowther (University of Cambridge, UK)]. elavGS and
UAS-lines were backcrossed six times into the w1118 genetic
background. Male flies expressing UAS-constructs were crossed to
female flies expressing elavGS, and adult-onset neuronal expres-
sion induced in female progeny by treatment with mifepristone
(RU486; at indicated concentrations) added to the standard
sucrose yeast (SY) medium.
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Lifespan analyses
Flies were raised at a standard density on SY medium in
200 mL bottles. Two days after eclosion once-mated females were
transferred to experimental vials containing SY medium with or
without RU486 (at indicated concentrations) at a density of 10 flies
per vial. Deaths were scored and flies were transferred to fresh
food 3 times a week. Data are presented as cumulative survival
curves, and survival rates were compared using log-rank tests. To
control for the effects of duration of exposure to Arc Ab42 peptide
and the direct effects of ageing on survival, survival from the age of
induction was expressed as a percentage of non-RU-treated
controls of the same age. Relative survival was compared between
groups using the Wilcoxon matched pairs sign rank test.
Negative Geotaxis Assays
To characterise effects of Arctic Ab42 peptide on neuronal
function, climbing assays were performed according to previously
published methods [38]. Climbing ability was analysed every 2–
3 days post-RU486 treatment. Briefly, 15 adult flies were placed in
a vertical column (25 cm long, 1.5 cm diameter) with a conic
bottom end, tapped to the bottom of the column, and their
subsequent climb to the top of the column was observed. Flies
reaching the top and flies remaining at the bottom of the column
after a 45 sec period were counted separately, and three trials were
performed at 1 min intervals for each experiment. Scores recorded
were the mean number of flies at the top (ntop), the mean number
of flies at the bottom (nbottom) and the total number of flies assessed
(ntot). A performance index (PI) defined asK(ntot + ntop – nbottom)/ ntot)
was calculated.
Quantification of total or soluble and insoluble Ab42
Total Ab42 was extracted based on previously published
methods [30]. Five fly heads were homogenised in 50 ml GnHCl
extraction buffer (5 M Guanidinium HCl, 50 mM Hepes pH 7.3,
protease inhibitor cocktail (Sigma, P8340) and 5 mM EDTA),
centrifuged at 21,000 g for 5 min at 4uC, and cleared supernatant
retained as the total fly Ab42 sample. Alternatively, soluble and
insoluble pools of Ab42 were extracted using a protocol adapted
from previously published methods [39]: 50 fly heads were
homogenised in 50 ml tissue homogenisation buffer (250 mM
sucrose, 20 mM Tris base, 1 mM EDTA, 1 mM EGTA, protease
inhibitor cocktail (Sigma)) then mixed further with 50 ml diethyl
acetate (DEA) buffer (0.4% DEA, 100 mM NaCl and protease
inhibitor cocktail). Samples were centrifuged at 135,000 g for one
hour at 4uC (Beckman OptimaTM Max centrifuge, TLA120.1
rotor), and supernatant retained as the cytosolic, soluble Ab42
fraction. Pellets were further resuspended in 200 mls ice-cold
formic acid (FA; 70%), and sonicated four times for 15 sec on ice.
Samples were re-centrifuged at 135,000 g for one hour at 4uC,
then 100 ml of supernatant diluted with 1 ml FA neutralisation
buffer (1 M Tris base, 0.5M Na2HPO4, 0.05% NaN3) and
retained as the insoluble, formic acid-extractable Ab42 fraction.
Total, soluble or insoluble Ab42 content was measured in Arctic
Ab42 flies and controls using the High Sensitivity Human Amyloid
Ab42 ELISA kit (Millipore). Total Ab42 samples were diluted
1:100, and soluble versus insoluble Ab42 samples diluted 1:10 in
sample/standard dilution buffer, then ELISA performed accord-
ing to the manufacturers’ instructions. Protein extracts were
quantified using the Bradford protein assay (Bio-Rad laboratories
Ltd, UK) and the amount of Ab42 in each sample expressed as a
ratio of the total protein content (pmoles/g total protein).
Quantitative RT-PCR
Total RNA was extracted from 20–25 fly heads using Trizol
(GIBCO) according to the manufacturers’ instructions. The
concentration of total RNA purified for each sample was
measured using an eppendorf biophotometer. 1 mg of total RNA was
then subjected to DNA digestion using DNAse I (Ambion),
immediately followed by reverse transcription using the Super-
script II system (Invitrogen) with oligo(dT) primers. Quantitative
PCR was performed using the PRISM 7000 sequence-detection
system (Applied Biosystems), SYBR Green (Molecular Probes),
ROX Reference Dye (Invitrogen), and Hot Star Taq (Qiagen,
Valencia, CA) by following manufacturers’ instructions. Each
sample was analysed in triplicate with both target gene (Arctic
Ab42) and reference gene (RP49, eIF-1A and aTubulin84)
primers in parallel. The primers for the Ab transgenes were
directed to the 59 end and 39 end of the Ab coding sequence:
forward GATCCTTCTCCTGCTAACC, reverse CACCAT-
CAAGCCAATAATCG. The reference gene primers were as
follows: RP49 forward ATGACCATCCGCCCAGCATCAGG
and reverse ATCTCGCCGCAGTAAACG; eIF-1A forward
ATCAGCTCCGAGGATGACGC and reverse GCCGAGACA-
GACGTTCCAGA; aTubulin84 forward TGGGCCCGTC-
TGGACCACAA and reverse TCGCCGTCACCGGAGTCCAT
[40].
Proteasome activity
Fly heads were homogenized in 25 mM Tris, pH 7.5 and
protein content determined by Bradford assay. Chymotrypsin-like
peptidase activity of the proteasome was assayed using the
fluorogenic peptide substrate Succinyl-Leu-Leu-Val-Tyr-amido-
methylcoumarin (LLVY-AMC), based on a previously published
protocol [41]. 20 mg of crude fly head homogenate total protein
was incubated at 37uC with 25 mM LLVY-AMC in a final volume
of 200 mLs. Enzymatic kinetics were conducted in a temperature-
controlled microplate fluorimeter (Tecan Infinite M200), at
excitation/emission wavelengths of 360/460 nm, measuring
fluorescence every two minutes for 30 min. Proteasome activity
was determined as the slope of AMC accumulation over time per
mg of total protein (pmoles/min/mg).
35S-methionine incorporation
Protein translation was measured in fly heads using a method
adapted from [42]. Standard SY medium was first supplemented
with 100mCi 35S methionine/ml of food (American Radiolabeled
Chemicals 1 mCi/37MBq ARS0104A). 15 flies were transferred
to each vial containing 1 ml radioactive SY medium. After three-
hours of feeding, flies were transferred to non-radioactive SY for
30 min in order to purge any undigested radioactive food from the
intestines. Flies that were in contact with the radioactive food for
1 minute were used as a background control. Flies were then
decapitated using liquid nitrogen and the heads homogenized in
1% SDS and heated for 5 minutes at 95uC. Samples were then
centrifuged twice for 5 minutes at 16,000 g. Proteins were
precipitated by the addition of the same volume of 20% cold
TCA (10% TCA final concentration) and incubated for 15 min-
utes on ice. Samples were then centrifuged at 16,000 g for
15 minutes, the pellet washed twice with acetone and then
resuspended in 200 ml of 4 M guanidine-HCl.
Samples (100 mls) were mixed with 3 mls of scintillant (Fluoran-
Safe 2, BDH) and radioactivity counted in a liquid scintillation
analyzer (TriCarb 2800TR, Perkin Elmer), with appropriate
quench corrections. SDS-homogenates, prior to TCA precipita-
tion, were also sampled and analysed as a measure of the total
radioactivity (incorporated and un-incorporated) present. Total
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protein for each sample was determined by Bradford assay and a
translation index was calculated as follows: (TCA protein cpm/
total cpm)/mg protein per sample.
Statistical analyses
Data are presented as means 6 SEM obtained in at least three
independent experiments. Log-rank, Wilcoxon matched pairs sign
rank, analysis of variances (ANOVA) and Tukey’s HSD (honestly
significant difference) post-hoc analyses were performed using JMP
(version 7.0) software (SAS Institute, Cary, NC, USA).
Supporting Information
Figure S1 Effects of RU486 treatment on lifespan of
control flies. Survival curves of elavGS/+, UAS-ArcticAb42/+
and UAS-ArcticAb42/+; elavGS/+ flies treated chronically with
200 mM RU486 from 2 days post-eclosion. Median lifespans (Log-
rank test P values): elavGS/+, 73.5 days for 2RU and 76 days for
+RU 200 (P=0.1306); UAS-ArcticAb42/+, 71 days for2RU and
73.5 days for +RU 200 (P= 0.08); UAS-ArcticAb42/+; elavGS/+
71 days for 2RU and 38.5 days for +RU 200 (P,0.0001).
(EPS)
Figure S2 Arctic Ab42 mRNA equalisation in young and
old flies. (A) Arctic Ab42 mRNA expression levels in the heads of
UAS-Arctic Ab42/+; elavGS/+ females treated with 0, 50, 100
and 200 mM RU486, for 1 week, from 5 days and 20 days post-
eclosion. Data are means 6 SEM (n= 5 for each group) and were
compared using two-way ANOVA and Tukey’s HSD post-hoc
analyses. There was no significant difference between young-
induced flies at 50 mM and old-induced flies at 100 and 200 mM
RU486 (P,0.05 comparing young-induced flies at 100 and
200 mM to all other conditions).
(EPS)
Figure S3 Proteasome activity declines with age in
control flies. Proteasome activity in the heads of elavGS/+ flies
treated with or without RU486 under the same conditions as
described in Figure 2E. Data are presented as mean activities
(pmoles/min/mg protein) 6 SEM (n= 5). *** P,0.0002 compar-
ing 9 versus 27 day-old flies, P=0.635 comparing + versus –
RU486 (two-way ANOVA); P,0.05 comparing RU 50 [2–9d] to
RU 200 [20–27d] flies and –RU day 9 to –RU day 27 flies
(Tukey’s HSD).
(EPS)
Figure S4 Arctic Ab42 protein equalisation in young and
old flies. Total (soluble and insoluble) Ab42 protein levels in the
heads of UAS-Arctic Ab42/+; elavGS/+ females pulsed with
various RU486 concentrations (50 mM–200 mM), for 1 or 2 weeks,
from days 5, 20 and 30 post-eclosion. Arctic Ab42 protein levels
were quantified at the end of each pulse. Data are means 6 SEM
(n=5 for each group) and were compared using two-way ANOVA
and Tukey’s HSD analyses for each induction period. There were
no significant differences between 5 day and 20 day-old flies
treated with 200 mM RU for 1 week, or 5 day old flies on 100 mM
RU and either 20 or 30 day old flies on 200 mM RU for 2 weeks.
(EPS)
Figure S5 Survival analysis of inducible Arctic Ab42 flies
treated either conditionally or chronically with RU486.
(A) Original survival curves of flies depicted in Figure 3B. UAS-
Arctic Ab42/+; elavGS/+ females were conditionally treated with
100 mM RU486 (RU) from 5-days and 200 mM RU486 from 20-
and 30-days post-eclosion for 2 weeks only, and were maintained
on 2RU prior to and following the RU pulse. Arrows indicate the
induction period, and Ab42 protein levels were equalised at the
end of the RU486 pulse (Fig 3A). Median lifespans were: 78 days
for 2RU, 57 days for +RU 100 [5–19d], 60 days for + RU 200
[20–34d] and 67 days for + RU 200 [30–44d]. Log rank test and P
values: P,0.0001 comparing 2RU versus +RU 100 [5–19d], +
RU 200 [20–34d] and + RU 200 [30–44d], P,0.05 comparing
+RU 100 [5–19d] versus + RU 200 [20–34d], and P,0.0001
comparing +RU 100 [5–19d] and +RU 200 [20–34d] versus +
RU 200 [30–44d]. (B) Survival curves of day 44 survivors only
from the experiment depicted in (A). Median lifespans were:
36 days for 2RU, 18 days for +RU 100 [5–19d], 18 days for +
RU 200 [20–34d] and 25 days for + RU 200 [30–44d]. Log rank
test and P values: P,0.0001 comparing2RU versus +RU 100 [5–
19d], + RU 200 [20–34d] and + RU 200 [30–44d], P=0.08
comparing +RU 100 [5–19d] versus + RU 200 [20–34d] and
P,0.0001 comparing +RU 100 [5–19d] and + RU 200 [20–34d]
versus + RU 200 [30–44d]. (C) Relative survival of +RU 100 [5–
19d] flies, expressed as a percentage of 2RU controls and plotted
from progressively later ages (5, 20 and 30d). Older flies exhibit a
significantly greater reduction in relative survival in response to
Arctic Ab42 expression than younger flies (P,0.0001 comparing
20d and 30d with 5d survivors, and 20d with 30d survivors,
Wilcoxon matched pairs sign rank test). (D) Original survival
curves of UAS-Arctic Ab42/+; elavGS/+ flies depicted in
Figure 4C. Arrows indicate the age of induction, from which flies
were treated chronically with 200 mM RU486. Median lifespans
were: 75 days for 2RU, 41 days for +RU 200 2d and 56 days for
+RU 200 20d. Log rank test and P values: P,0.0001 comparing
2RU versus +RU 200 2d and +RU 200 20d, and +RU 200 2d
versus +RU 200 20d.
(EPS)
Table S1 Details of RU486 pulse conditions used in
acute induction experiments. Note that these are days post-
eclosion and that all flies were treated with RU486 at the same age
(day 2 post-eclosion).
(DOC)
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